AcroMeta Group Limited (SGX: 43F), a facility management services provider listed on the Catalist board of the Singapore Exchange, announced on September 7, 2026, that it has entered into a non-binding term sheet with Macro HRD SG Pte. Ltd. (Macro), a Singapore-based management consultancy for the healthcare sector. The term sheet outlines a strategic partnership where AcroMeta will acquire a strategic stake in Macro-ATCLS Pte. Ltd. (Macro-ATCLS), the commercial vehicle for Macro's Ambient Temperature Cellular Logistics (ATCLS) technology, and holds an option to secure an exclusive license to deploy the technology across Southeast Asia.
ATCLS is an emerging technology that aims to transform the transportation of living cells and temperature-sensitive biological materials by eliminating the need for conventional refrigerated and cryogenic cold chains. The technology uses proprietary ambient-temperature preservation and reactivation methods, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity, and process control. This enables dormant living cells to be transported at ambient temperatures and reactivated at the point of use, offering potential reductions in cost, fragility, and geographic limitations compared to traditional cold-chain logistics.
The market opportunity is substantial. According to project materials cited in the announcement, the global cell-and-gene-therapy 3PL market was estimated at US$1.81 billion in 2025 and is projected to reach US$16.95 billion by 2035, representing a compound annual growth rate of 25.1%. The underlying markets include immune-cell therapy (US$5.2 billion), organ transplantation (US$47 billion), and other segments like stem cells, gene therapy, and regenerative medicine. Macro-ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032. These figures were provided by Macro's management and have not been independently verified by AcroMeta's board.
Under the proposed arrangement, AcroMeta will have the option to acquire an exclusive license to deploy ATCLS technology in agreed Southeast Asian territories, including the right to appoint sub-licensees. This structure is intended to give AcroMeta rights to develop and commercialize the ATCLS business in the region, with a first right to acquire additional territories, expanding the Group's potential commercial reach.
Mr. Lawrence Toh, Executive Director of AcroMeta Group Limited, commented, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
AcroMeta's move into this high-growth sector aligns with its strategy to diversify beyond its core facility management operations. The Group intends to continue evaluating strategic opportunities to support long-term value creation for shareholders, with a focus on disciplined capital allocation.
For more information about AcroMeta, visit www.AcroMeta.com. The original press release is available at www.newmediawire.com.
